kabutan
N225

65,269.33

-1.70%

TOPIX

4,050.33

-1.83%

USDJPY

153.85

-0.34%

Kabutan Concierge Closed Beta - Apply now

RaQualia Pharma rebounds for first time in four sessions after receiving patent approval in South Korea for TRPV4 antagonist

Thu Sep 3, 2026 9:32 am JST Catalyst

RaQualia Pharma Inc. <4579> rebounded for the first time in four sessions after announcing after market close on the 2nd that it received patent approval in South Korea for a substance patent covering its pyrimidin-4(3H)-one derivative, a TRPV4 antagonist. The announcement drew buying interest.

The company's TRPV4 antagonist has demonstrated high efficacy in multiple animal models of pain, inflammation, and eye diseases. The compound previously received patent approvals in China, Japan, Europe, and the U.S.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.